Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: A randomized clinical trial

JAMA Psychiatry

Volumn 73, Issue 9, 2016, Pages 928-937

  Anagnostou, Evdokia ^a,b   Aman, Michael G ^a,c   Handen, Benjamin L ^d   Sanders, Kevin B ^a,e   Shui, Amy ^f   Hollway, Jill A ^a,c   Brian, Jessica ^a,b   Arnold, L Eugene ^a,c   Capano, Lucia ^a   Hellings, Jessica A ^a,c   Butter, Eric ^g,h   Mankad, Deepali ^a,b   Tumuluru, Rameshwari ^d   Kettel, Jessica ^d   Newsom, Cassandra R ^e   Hadjiyannakis, Stasia ⁱ   Peleg, Naomi ^a   Odrobina, Dina ^a   McAuliffe Bellin, Sarah ^d   Zakroysky, Pearl ^f   Marler, Sarah ^a,e   Wagner, Alexis ^a,c   Wong, Taylor ^a,c   Macklin, Eric A ^f,j   Veenstra Vander Weele, Jeremy ^k,l,m   more..

^a University of Toronto   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g NATIONWIDE CHILDREN S HOSPITAL   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^j HARVARD MEDICAL SCHOOL   (United States)

^k Och Spine at New York Presbyterian Hospitals   (United States)

^l NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^m NEW YORK PRESBYTERIAN HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; ILOPERIDONE; INSULIN; METFORMIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE; NEUROLEPTIC AGENT;

ABDOMINAL DISCOMFORT; ABNORMAL FECES; AGGRESSION; AGITATION; ANGER; ANXIETY; ARTICLE; AUTISM; BACKACHE; BODY COMPOSITION; BODY MASS; CHAPPED LIPS; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR INFECTION; FATIGUE; FEMALE; FEVER; FLATULENCE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITAL ADMISSION; HUMAN; INCREASED APPETITE; INSOMNIA; INSULIN BLOOD LEVEL; INTENTION TO TREAT ANALYSIS; IRRITABILITY; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NAUSEA; NOSE OBSTRUCTION; OBESITY; OTITIS MEDIA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; SEDATION; SIDE EFFECT; SINUSITIS; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; ADOLESCENT; AUTISM SPECTRUM DISORDER; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MULTICENTER STUDY; OVERWEIGHT;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; AUTISM SPECTRUM DISORDER; BODY MASS INDEX; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; METFORMIN; OVERWEIGHT; WEIGHT GAIN;

EID: 84996606750     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2016.1232     Document Type: Article

References (43)

1. McCracken JT,McGough J, Shah B, et al; Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314-321.
2. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005;162 (6):1142-1148.
3. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J AmAcad Child Adolesc Psychiatry. 2009;48(11):1110-1119.
4. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009; 124(6):1533-1540.
5. Aman MG, KasperW, Manos G, et al. Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. J Child Adolesc Psychopharmacol. 2010;20(5):415-422.
6. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5): e634-e641.
7. Martin A, Scahill L, Anderson GM, et al.Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry. 2004;161(6):1125-1127.
8. Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 2005;15(6):869-884.
9. BoboWV, CooperWO, Stein CM, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70(10):1067-1075.
10. Galling B, Roldán A, Nielsen RE, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: A systematic review and meta-analysis. JAMA Psychiatry. 2016;73(3):247-259.
11. Lindsay RL, Leone S, Aman MG. Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clin Pediatr (Phila). 2004;43(5):437-444.
12. Hellings JA, Zarcone JR, Crandall K,Wallace D, Schroeder SR.Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol. 2001;11(3):229-238.
13. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry. 2005;162(7):1361-1369.
14. Bouza C, López-Cuadrado T, Gutierrez-Torres LF, Amate J. Efficacy and safety ofmetformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis. Obes Facts. 2012;5(5):753-765.
15. Yanovski JA, Krakoff J, Salaita CG, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: A randomized clinical trial. Diabetes. 2011;60(2): 477-485.
16. ZhengW, Li XB, Tang YL, Xiang YQ,Wang CY, de Leon J. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2015;35(5):499-509.
17. Jarskog LF, Hamer RM, Catellier DJ, et al; METS Investigators. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170(9):1032-1040.
18. Wu RR, Jin H, Gao K, et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: A double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2012;169 (8):813-821.
19. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072-2079.
20. Shin L, Bregman H, Breeze JL, Noyes N, Frazier JA.Metformin for weight control in pediatric patients on atypical antipsychotic medication. J Child Adolesc Psychopharmacol. 2009;19(3):275-279.
21. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry. 2002; 159(4):655-657.
22. Arman S, Sadramely MR, Nadi M, Koleini N. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J. 2008;29(8):1130-1134.
23. Gonçalves P, Araújo JR, Martel F. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol. 2015;25(1):1-16.
24. Ibrahim SH, Voigt RG, Katusic SK,Weaver AL, BarbaresiWJ. Incidence of gastrointestinal symptoms in children with autism: A population-based study. Pediatrics. 2009;124(2): 680-686.
25. World Medical Association.World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
26. Lord C, Rutter M, DiLavore PC, Risi S. Autism Diagnostic Observation Schedule: A Standardized Observation of Communicative and Social Behavior. Los Angeles, CA: Western Psychological Services; 1999.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Health Disorders. 4th ed.Washington, DC: American Psychiatric Association; 1994.
28. Roid GH. Stanford-Binet Intelligence Scales. 5th ed. Itasca, IL: Riverside Publishing; 2003.
29. Mullen EJ. Mullen Scales of Early Learning. Bloomington, MN: Pearson Assessments; 1989.
30. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985a;89(5):485-491.
31. Aman MG, Pearson DA. Monitoring and measuring drug effects, II: behavioral, emotional, and cognitive effects. In:Werry JS, Aman MG. Practitioner's Guide to Psychoactive Drugs for Children and Adolescents. 2nd ed. New York, NY: Plenum Press; 1999:99-164.
32. Greenhill LL, Vitiello B, Fisher P, et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J AmAcad Child Adolesc Psychiatry. 2004;43(12):1488-1496.
33. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7): 412-419.
34. Mazefsky CA, Schreiber DR, Olino TM, Minshew NJ. The association between emotional and behavioral problems and gastrointestinal symptoms among children with high-functioning autism. Autism. 2014;18(5):493-501.
35. Nikolov RN, Bearss KE, Lettinga J, et al. Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. J Autism Dev Disord. 2009;39(3):405-413.
36. McGuire K, Fung LK, Hagopian L, et al. Irritability and problem behavior in autism spectrum disorder: A practice pathway for pediatric primary care. Pediatrics. 2016;137(suppl 2):S136-S148.
37. Aman MG, Singh NN, Stewart AW, Field CJ. Psychometric characteristics of the aberrant behavior checklist. Am J Ment Defic. 1985b;89(5): 492-502.
38. GuyW. Dosage Record and Treatment Emergent Symptoms Scale, ECDEU Assessment Manual for Psychopharmacology (Revised). Washington, DC: US Dept of Health Education & HumanWelfare; 1976:223-244.
39. Kieser M, Friede T. Simple procedures for blinded sample size adjustment that do not affect the type I error rate. Stat Med. 2003;22(23):3571-3581.
40. Fitzmaurice G, Laird N,Ware J. Applied Longitudinal Analysis. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2011.
41. Valeri L, Vanderweele TJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods. 2013;18(2):137-150.
42. McElroy SL, Frye MA, Altshuler LL, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord. 2007;9(4):426-434.
43. Penzner JB, Dudas M, Saito E, et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol. 2009;19(5):563-573.